Stock EH3A AMARIN CORPORATION PLC (ADR)
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

Amarin Corporation plc (ADR) Share Price Xetra

Equities

EH3A

US0231112063

Biotechnology & Medical Research

Real-time Estimate Tradegate
Other stock markets
 21:00:41 10/06/2024 BST
0.62 EUR 0.00% Intraday chart for Amarin Corporation plc (ADR)
06-06 Tech Firms Lead European Equities Traded in the US as American Depositary Receipts Higher in Thursday Trading MT
06-05 European Equities Traded in the US as American Depositary Receipts Rise in Wednesday Trading MT
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Days!
Take advantage of the offer
* See conditions on site

Financials

Sales 2024 * 202M 188M 15.88B Sales 2025 * 215M 200M 16.88B Capitalization 277M 257M 21.72B
Net income 2024 * -70M -65.03M -5.5B Net income 2025 * -64M -59.46M -5.03B EV / Sales 2024 * 1.15 x
Net cash position 2024 * 43.92M 40.8M 3.45B Net cash position 2025 * 159M 147M 12.46B EV / Sales 2025 * 0.55 x
P/E ratio 2024 *
-3.82 x
P/E ratio 2025 *
-4.05 x
Employees -
Yield 2024 *
-
Yield 2025 *
-
Free-Float 90.48%
More Fundamentals * Assessed data

Latest news about Amarin Corporation plc (ADR)

Tech Firms Lead European Equities Traded in the US as American Depositary Receipts Higher in Thursday Trading MT
European Equities Traded in the US as American Depositary Receipts Rise in Wednesday Trading MT
Sector Update: Health Care Stocks Rise Late Afternoon MT
Sector Update: Health Care Stocks Rise Tuesday Afternoon MT
Sector Update: Health Care MT
Amarin Shares Fall After CEO Resignation MT
European Equities Traded in the US as American Depositary Receipts Trend Lower in Tuesday Trading MT
Amarin Names Aaron Berg as Chief Executive Officer MT
Amarin Corporation plc Announces CEO Changes CI
Amarin Corporation plc Announces Executive Changes CI
European Equities Traded in the US as American Depositary Receipts Open Week Lower in Tuesday Trading MT
Amarin Says Greece Approves Vazkepa for National Reimbursement; Signs Commercialization Agreement With Vianex MT
Amarin Corporation plc Receives National Reimbursement for Vazkepa (Icosapent Ethyl) in Greece by Greek Ministry of Health CI
Amarin Corporation plc Announces Exclusive Marketing and Commercialization Agreement with Vianex S.A CI
European Equities Traded in the US as American Depositary Receipts Kick Off Week Higher MT
More news

Latest transcript on Amarin Corporation plc (ADR)

Logo Amarin Corporation plc (ADR)
Amarin Corporation plc, Q1 2024 Earnings Call, May 01, 2024
More transcripts

Analyst Recommendations on Amarin Corporation plc (ADR)

Jefferies Downgrades Amarin to Hold From Buy, Cuts Price Target to $1 From $3 MT
Northland Adjusts Price Target on Amarin to $1.25 From $2, Maintains Market Perform Rating MT
Jefferies Upgrades Amarin to Buy From Hold, Adjusts Price Target to $3 From $1.30 MT
European Equities Follow US Markets Lower on Interest Rate Concerns MT
SVB Securities Adjusts Amarin's Price Target to $2 From $3, Maintains Market Perform Rating MT
More recommendations

Press releases Amarin Corporation plc (ADR)

Amarin Board of Directors Announces CEO Transition GL
Amarin Board of Directors Announces CEO Transition AQ
AMARIN RECEIVES NATIONAL REIMBURSEMENT FOR VAZKEPA IN GREECE AND ANNOUNCES EXCLUSIVE MARKETING AND COMMERCIALIZATION AGREEMENT WITH VIANEX S.A. AQ
 Amarin Receives National Reimbursement for VAZKEPA® (icosapent ethyl) in Greece and Announces Exclusive Marketing and Commercialization Agreement with Vianex S.A. GL
Amarin to Present at H.C. Wainwright 2nd Annual BioConnect Investor Conference GL
More press releases

News in other languages on Amarin Corporation plc (ADR)

Amarin reçoit un remboursement pour VAZKEPA® en Suède
Amarin recibe reembolso por VAZKEPA® en Suecia
Amarin erhält Kostenerstattung für VAZKEPA® in Schweden
Une récente analyse démontre que VASCEPA® (icosapent éthyl) a considérablement réduit le risque d'événements cardiovasculaires potentiellement mortels chez des patients ayant déjà subi une intervention coronaire percutanée
Jüngste Analysen zeigen, dass VASCEPA® (Icosapent-Ethyl) das Risiko potenziell tödlicher kardiovaskulärer Ereignisse bei Patienten mit vorheriger perkutaner Koronarintervention signifikant gesenkt hat
More news

Managers and Directors - Amarin Corporation plc (ADR)

Managers TitleAgeSince
Aaron Berg CEO
 Chief Executive Officer 61 31/10/12
Thomas Reilly DFI
 Director of Finance/CFO 52 19/06/22
Jonathan Provoost CMP
 Compliance Officer 55 11-14
Members of the board TitleAgeSince
Louis Sterling BRD
 Director/Board Member 45 27/02/23
Odysseas Kostas CHM
 Chairman 49 27/02/23
Keith Horn BRD
 Director/Board Member 66 27/02/23
More insiders

Company Profile

Amarin Corporation PLC is a pharmaceutical company. The Company is focused on the commercialization and development of therapeutics to improve cardiovascular (CV), health and reduce CV risk. The Company operates through the development and commercialization of VASCEPA. Its lead product, Vascepa (icosapent ethyl) capsule is used as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia. This indication for Vascepa, known as the MARINE indication, is based primarily on the results from the MARINE study of Vascepa in this approved patient population. The Company sells Vascepa principally to wholesalers, as well as selected regional wholesalers and specialty pharmacy providers, or collectively, its distributors, which in turn resell Vascepa to retail pharmacies for resale to patients and healthcare providers.
Sector
Biotechnology & Medical Research
Calendar
30/07/2024 - Q2 2024 Earnings Release (Projected)
More about the company

Sector Bio Therapeutic Drugs

1st Jan change Capi.
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
+18.77% 125B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+14.05% 108B
BIONTECH SE Stock BioNTech SE
-7.16% 24.21B
ARGENX SE Stock argenx SE
+2.07% 22.78B
GENMAB A/S Stock Genmab A/S
-10.79% 17.96B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-41.74% 16.43B
BEIGENE, LTD. Stock BeiGene, Ltd.
-13.47% 16.37B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+2.23% 13.58B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+27.13% 11.66B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. AMRN Stock
  4. EH3A Stock
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW